DRDO develops anti-COVID-19 drug which aids in faster recovery of patients

NEW DELHI: The Defence Research and Development Organisation (DRDO) has developed an anti-COVID-19 oral drug, which has been authorised by the Drugs Controller General of India (DCGI), for emergency use as adjunct therapy in moderate to extreme coronavirus patients.

The medication comes in powder form in a sachet and is taken by dissolving it in water.

ALSO READ: Tripura royal scion Pradyot Deb Barma to donate his entire salary for…

The anti-Covid therapeutic application of the drug 2-deoxy-D-glucose was developed by a DRDO lab and Hyderabad-based Dr Reddy's Laboratories (2-DG).

After clinical trial, findings showed that a molecule present in the drug aids in the faster recovery of hospitalised patients and decreases supplementary oxygen dependency.

In RT-PCR tests, a higher percentage of patients treated with the drug tested negative for Covid.

The drug was found to be safe in COVID-19 patients in the second phase of trials, which took place between May and October of last year, and showed substantial progress in their recovery.

A total of 110 patients took part in the second round.

ALSO READ: Modi government has failed people of India: Sonia Gandhi

Although the third round of trials took place in six hospitals across India, "dose ranging" took place in 11 hospitals.

Massive foreign assistance is pouring in as India reports a shortage of essential medicines, medical oxygen, and other supplies required for COVID patients after the country's healthcare system was crippled by a sudden surge in COVID-19 cases.

Even as more states placed lockdowns in a desperate attempt to stop the devastating new surge, India reported 4,187 coronavirus deaths today, the highest daily count so far.

Over 4.01 lakh new infections were reported, bringing the total number of cases to over 2.18 million.

Follow us on Facebook